{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:43:34Z","timestamp":1785465814551,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SMN-139151"],"award-info":[{"award-number":["SMN-139151"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SMN-139148"],"award-info":[{"award-number":["SMN-139148"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SMN-139150"],"award-info":[{"award-number":["SMN-139150"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SMN-139149"],"award-info":[{"award-number":["SMN-139149"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014405","name":"Centre for Addiction and Mental Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030995","name":"Bioprojet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010523","name":"Centre for Addiction and Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010523","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016549","name":"Universal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015070","name":"Department of Psychiatry, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.josat.2025.209743","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:35:47Z","timestamp":1750793747000},"page":"209743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The effect of craving on retention and treatment switching under buprenorphine-naloxone and methadone models of care for non-heroin opioid use disorder: Exploratory analyses from a pragmatic, randomized controlled trial"],"prefix":"10.1016","volume":"176","author":[{"given":"Christina","family":"McAnulty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bastien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Bahremand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Ledjiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Eugenia","family":"Socias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Christophe","family":"Juteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Jutras-Aswad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.josat.2025.209743_bb0005","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1503\/cmaj.181506","article-title":"Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs","volume":"191","author":"Artenie","year":"2019","journal-title":"Canadian Medical Association Journal"},{"issue":"6","key":"10.1016\/j.josat.2025.209743_bb0010","doi-asserted-by":"crossref","first-page":"224","DOI":"10.24095\/hpcdp.38.6.02","article-title":"The opioid crisis in Canada: A national perspective","volume":"38","author":"Belzak","year":"2018","journal-title":"Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice"},{"key":"10.1016\/j.josat.2025.209743_bb0015","unstructured":"Brief Substance Craving Scale | Data Share 2.0. (n.d.). Retrieved January 28, 2022, from https:\/\/datashare.nida.nih.gov\/instrument\/brief-substance-craving-scale."},{"issue":"4","key":"10.1016\/j.josat.2025.209743_bb0020","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/add.12834","article-title":"A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia","volume":"110","author":"Burns","year":"2015","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.josat.2025.209743_bb0025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","article-title":"The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis","volume":"71","author":"Ciccarone","year":"2019","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.josat.2025.209743_bb0030","author":"CRISM National Guideline Review Committee"},{"issue":"6","key":"10.1016\/j.josat.2025.209743_bb0035","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: A systematic review and meta-analysis of randomised and observational studies","volume":"10","author":"Degenhardt","year":"2023","journal-title":"The Lancet Psychiatry"},{"issue":"10208","key":"10.1016\/j.josat.2025.209743_bb0040","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","article-title":"Global patterns of opioid use and dependence: Harms to populations, interventions, and future action","volume":"394","author":"Degenhardt","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.josat.2025.209743_bb0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drugalcdep.2018.04.024","article-title":"Crude estimates of prescription opioid-related misuse and use disorder populations towards informing intervention system need in Canada","volume":"189","author":"Fischer","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.josat.2025.209743_bb0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M17-0865","article-title":"Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 national survey on drug use and health","volume":"167","author":"Han","year":"2017","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1016\/j.josat.2025.209743_bb0055","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12888-017-1415-y","article-title":"Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine","volume":"17","author":"Heikman","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.josat.2025.209743_bb0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.addbeh.2018.10.020","article-title":"Substance use disorders and PTSD: Examining substance use, PTSD symptoms, and dropout following imaginal exposure","volume":"90","author":"Jarnecke","year":"2019","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.josat.2025.209743_bb0065","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.21090964","article-title":"Flexible buprenorphine\/naloxone model of care for reducing opioid use in individuals with prescription-type opioid use disorder: An open-label, pragmatic, noninferiority randomized controlled trial","author":"Jutras-Aswad","year":"2022","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.josat.2025.209743_bb0070","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3389\/fpsyt.2019.00592","article-title":"Craving in opioid use disorder: From neurobiology to clinical practice","volume":"10","author":"Kakko","year":"2019","journal-title":"Frontiers in Psychiatry"},{"issue":"1","key":"10.1016\/j.josat.2025.209743_bb0075","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13643-021-01764-9","article-title":"Retention in opioid agonist treatment: A rapid review and meta-analysis comparing observational studies and randomized controlled trials","volume":"10","author":"Klimas","year":"2021","journal-title":"Systematic Reviews"},{"issue":"2","key":"10.1016\/j.josat.2025.209743_bb0080","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/aje\/kwp107","article-title":"Competing risk regression models for epidemiologic data","volume":"170","author":"Lau","year":"2009","journal-title":"American Journal of Epidemiology"},{"key":"10.1016\/j.josat.2025.209743_bb0085","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.josat.2025.209743_bb0090","doi-asserted-by":"crossref","first-page":"109604","DOI":"10.1016\/j.drugalcdep.2022.109604","article-title":"Buprenorphine\/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial","volume":"239","author":"McAnulty","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209743_bb0095","doi-asserted-by":"crossref","first-page":"108023","DOI":"10.1016\/j.addbeh.2024.108023","article-title":"Mediating effect of craving on the impact of buprenorphine\/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial","volume":"154","author":"McAnulty","year":"2024","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.josat.2025.209743_bb0100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drugalcdep.2014.10.002","article-title":"Assessing craving and its relationship to subsequent prescription opioid use among treatment-seeking prescription opioid dependent patients","volume":"145","author":"McHugh","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"issue":"10","key":"10.1016\/j.josat.2025.209743_bb0105","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1037\/ccp0000399","article-title":"Effects of craving on opioid use are attenuated after pain coping counseling in adults with chronic pain and prescription opioid addiction","volume":"87","author":"Messina","year":"2019","journal-title":"Journal of Consulting and Clinical Psychology"},{"issue":"3","key":"10.1016\/j.josat.2025.209743_bb0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1300\/J069v20n03_07","article-title":"The measurement of craving","volume":"20","author":"Mezinskis","year":"2001","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.josat.2025.209743_bb0115","unstructured":"Mezinskis, Somoza, H., Wishnick, H., Kidwell, C., Dyrenforth, T., Winhusen, T., & Kropp, F. (1998). Inter-correlations between several cocaine craving scales and their relationship to recent cocaine use. Problems of drug dependence 1998: Proceedings of the 60th annual scientific meeting the college on problems of drug dependence, Inc., 179."},{"issue":"5","key":"10.1016\/j.josat.2025.209743_bb0120","doi-asserted-by":"crossref","first-page":"e2411389","DOI":"10.1001\/jamanetworkopen.2024.11389","article-title":"Opioid Coprescription through risk mitigation guidance and opioid agonist treatment receipt","volume":"7","author":"Min","year":"2024","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2025.209743_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109932","article-title":"Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial","volume":"248","author":"Mocanu","year":"2023","journal-title":"Drug and Alcohol Dependence"},{"issue":"9","key":"10.1016\/j.josat.2025.209743_bb0130","first-page":"CD011117","article-title":"Opioid agonist treatment for people who are dependent on pharmaceutical opioids","volume":"9","author":"Nielsen","year":"2022","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"21","key":"10.1016\/j.josat.2025.209743_bb0135","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder","volume":"332","author":"Nosyk","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2025.209743_bb0140","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.drugalcdep.2019.05.026","article-title":"Stress, craving and mood as predictors of early dropout from opioid agonist therapy","volume":"202","author":"Panlilio","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209743_bb0145","series-title":"R: A language and environment for statistical computing [computer software]","author":"R Core Team","year":"2023"},{"issue":"25","key":"10.1016\/j.josat.2025.209743_bb0150","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.2174\/13816128113199990623","article-title":"Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: Implications for clinicians","volume":"20","author":"Roux","year":"2014","journal-title":"Current Pharmaceutical Design"},{"issue":"5","key":"10.1016\/j.josat.2025.209743_bb0155","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11920-024-01495-3","article-title":"Using measurement-based care as a precision medicine strategy for substance use disorders","volume":"26","author":"Samokhvalov","year":"2024","journal-title":"Current Psychiatry Reports"},{"issue":"5","key":"10.1016\/j.josat.2025.209743_bb0160","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/ADM.0b013e318297021e","article-title":"Meaning and methadone: Patient perceptions of methadone dose and a model to promote adherence to maintenance treatment","volume":"7","author":"Sanders","year":"2013","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2025.209743_bb0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cct.2018.04.001","article-title":"The OPTIMA study, buprenorphine\/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale","volume":"69","author":"Socias","year":"2018","journal-title":"Contemporary Clinical Trials"},{"key":"10.1016\/j.josat.2025.209743_bb0170","series-title":"In search of a universal drug craving scale. Paper presented at the annual meeting of the American Psychiatric Association, Miami Florida, 1995","author":"Somoza","year":"1995"},{"key":"10.1016\/j.josat.2025.209743_bb0175","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1016\/j.josat.2025.209743_bb0180","series-title":"Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on drug use and health","author":"Substance Abuse and Mental Health Services Administration","year":"2021"},{"key":"10.1016\/j.josat.2025.209743_bb0185","series-title":"Using time dependent covariates and time dependent coefficients in the cox model","author":"Therneau","year":"2021"},{"key":"10.1016\/j.josat.2025.209743_bb0190","author":"Therneau"},{"key":"10.1016\/j.josat.2025.209743_bb0195","series-title":"Modeling survival data: Extending the cox model","author":"Therneau","year":"2000"},{"key":"10.1016\/j.josat.2025.209743_bb0200","series-title":"United Nations Office on Drugs and Crime","author":"World Drug Report 2021","year":"2021"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:40:32Z","timestamp":1762652432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875925001225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"alternative-id":["S2949875925001225"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2025.209743","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of craving on retention and treatment switching under buprenorphine-naloxone and methadone models of care for non-heroin opioid use disorder: Exploratory analyses from a pragmatic, randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2025.209743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209743"}}